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C A N C E R
Mutant CEBPA directly drives the expression 
of the targetable tumor-promoting factor CD73 in AML
Janus S. Jakobsen1,2,3*†, Linea G. Laursen1,2,3†, Mikkel B. Schuster1,2,3†, Sachin Pundhir1,2,3,4, 
Erwin Schoof1,2,3, Ying Ge1,2,3, Teresa d’Altri1,2,3, Kristoffer Vitting-Seerup4, Nicolas Rapin1,2,3,4‡, 
Coline Gentil1,2,3, Johan Jendholm1,2,3, Kim Theilgaard-Mönch1,2,3,5, Kristian Reckzeh1,2,3, 
Lars Bullinger6, Konstanze Döhner7, Peter Hokland8, Jude Fitzgibbon9, Bo T. Porse1,2,3§
The key myeloid transcription factor (TF), CEBPA, is frequently mutated in acute myeloid leukemia (AML), but the 
direct molecular effects of this leukemic driver mutation remain elusive. To investigate CEBPA mutant AML, we per-
formed microscale, in vivo chromatin immunoprecipitation sequencing and identified a set of aberrantly activated 
enhancers, exclusively occupied by the leukemia-associated CEBPA-p30 isoform. Comparing gene expression 
changes in human CEBPA mutant AML and the corresponding CebpaLp30 mouse model, we identified Nt5e, encoding 
CD73, as a cross-species AML gene with an upstream leukemic enhancer physically and functionally linked to the 
gene. Increased expression of CD73, mediated by the CEBPA-p30 isoform, sustained leukemic growth via the 
CD73/A2AR axis. Notably, targeting of this pathway enhanced survival of AML-transplanted mice. Our data thus 
indicate a first-in-class link between a cancer driver mutation in a TF and a druggable, direct transcriptional target.
INTRODUCTION
Recent advances in our ability to sequence cancer genomes have left 
us with the challenge of translating this knowledge into tailor-made 
therapies targeting the characteristics of individual tumors, a concept 
frequently termed precision medicine. To harness the potential of 
precision medicine, we will need to identify oncogenic driver muta-
tions and understand how they sustain disease development and 
maintenance.
One of the best characterized cancer types is acute myeloid leukemia 
(AML), a heterogeneous group of hematopoietic clonal disorders 
characterized by rapid accumulation of immature myeloid blasts at the 
expense of normal hematopoiesis. Specific cancer driver mutations, 
which underlie the distinct molecular AML subtypes, are closely linked 
to therapy outcome and overall risk stratification (1–3). Frequently 
found classes of leukemia drivers include fusion proteins and mutations 
in NPM1 [Nucleophosmin (encoded by NPM1)], epigenetic modifiers, 
signaling pathways, and the spliceosome, as well as loss-of-function 
mutations in key myeloid transcription factors (TFs) (1).
Despite our detailed knowledge of AML genetics, treatment has 
remained largely unchanged for decades and survival rates are low (3). 
Exceptions are novel therapies exploiting the genetic abnormalities 
of specific subgroups to target specific molecular events driving ma-
lignant transformation. An example is treatment of patients with acute 
promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA), 
which overrides the differentiation block facilitated by the t(15:17) 
encoded PML-RARA fusion (4). Such an advancement emphasizes 
the importance of functionally characterizing the molecular patho-
genesis to find new AML subtype-specific targets.
The TF CEBPA is essential for normal myeloid differentiation 
(5, 6) and is mutated in approximately 10% of AML cases (7–9). The 
intron-less CEBPA gene is transcribed into a single mRNA, which is 
translated into two isoforms by alternative start codon usage: the 
full-length version termed p42 and a shorter version termed p30 that 
lacks the full trans-activation potential of p42. A frequently occurring 
class of CEBPA mutations in AML harbor CEBPA N-terminal nonsense 
or frameshift mutations, resulting in the exclusive expression of the 
p30 isoform from the mutated allele. C-terminal in-frame mutations 
interrupt DNA binding and homodimerization properties of the 
proteins and often co-occur on a separate allele from the N-terminal 
mutations (8). This pattern of mutations produces p30/p30 homodimers 
as the functional CEBPA TF entity in CEBPA mutant AML (10).
Biallelic CEBPA mutant AML is associated with an overall favorable 
clinical outcome (9) and constitutes a defined patient subgroup, 
corroborated by genetic subclassification (1) and gene expression 
profiling (7). The leukemia has been successfully modeled by the 
CebpaLp30 mouse line (termed Lp30) that contains an endogenous 
Cebpa mutation, resulting in the ablation of p42 expression, precisely 
mimicking the N-terminal CEBPA mutations in patients with AML. 
As a consequence, mice homozygous for the Lp30 allele are charac-
terized by a myeloid differentiation block in preleukemic animals. 
This condition subsequently progresses into myeloid hyperprolifer-
ation and ultimately leads to the development of an overt and trans-
plantable AML (11).
CEBPA has both activating and repressive activities. Among the 
transcriptionally activated targets are the genes encoding the myeloid- 
specifying G-CSFr, GM-CSFr, and MPO (12–14). Conversely, loss 
of CEBPA causes derepression of Cebpg (15) and Sox4 (16), both of 
which are crucial for maintaining leukemic cells in a dedifferentiated 
state. However, it is not understood how the specific loss of full-
length p42, and hence, the preferential p30/p30 homodimer formation 
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affect the gene regulatory landscape on a global level and ultimately 
drives leukemic progression.
In this study, we used a combination of gene expression and 
chromatin immunoprecipitation sequencing (ChIP-seq) analyses to 
decipher the direct regulatory function of p30 in AML. We compared 
highly purified populations of leukemic granulocytic monocytic 
progenitors (L-GMPs; Lin– cKit+ Sca1– CD150– CD41– FcgRII/III+) 
from both leukemic Lp30 mice and patients with AML to their closest 
healthy counterpart, GMPs. Using this approach, we identified Nt5e, 
encoding the ectoenzyme NT5E/CD73, as specifically up-regulated 
in biallelic CEBPA mutant leukemia as a consequence of p30 binding 
to a normally silenced upstream enhancer. CD73 catalyzes the con-
version of adenosine monophosphate (AMP) into immune-dampening 
adenosine and has been shown to provide an immune evasive micro-
environment in solid tumors. Correspondingly, an anti-tumor effect 
has previously been demonstrated upon blockade of the enzyme in 
cancers with CD73 expression. Here, we validated CD73 as a tumor- 
promoting factor in biallelic CEBPA mutant AML that can be targeted 
by dual inhibition of CD73 and adenosinergic signaling through the 
A2A receptor (A2AR), suggesting a novel precise treatment modality 
for this AML subtype.
RESULTS
CEBPA isoforms occupy specific genomic regions  
associated with distinct epigenetic profiles in normal 
and leukemic GMPs
To investigate the action of the cancer-driving CEBPA-p30 isoform, we 
performed ChIP-seq for CEBPA on phenotypically defined GMPs from 
wild-type (WT) and leukemic Lp30 mice isolated using fluorescence- 
activated cell sorting (FACS) (fig. S1A). In contrast to the Lp30 mouse 
model, solely expressing p30, WT GMPs almost exclusively express 
the full-length p42 isoform of CEBPA (11). Thus, for simplicity, we 
will refer to CEBPA in WT GMPs as p42, although, in addition to 
the predominant p42/p42 homodimer, these cells retain low levels 
of p42/p30 heterodimers and p30/30 homodimers. CEBPA genomic 
occupancy (Fig. 1A) was used to identify and subdivide stringent 
sets of regions bound by CEBPA either exclusively in leukemic GMPs 
(p30 regions), in WT GMPs (p42 regions), or shared between both 
conditions (common regions) (total of 30,951) (Fig. 1B and data file S1); 
87.7% of the CEBPA-bound regions are common, whereas 4.5 and 
7.9% are p42 and p30 specific, respectively (Fig. 1, B and C). ChIP-seq 
of histone 3 lysine 4 monomethyl (H3K4me1) and histone 3 lysine 
27 acetyl (H3K27ac) modifications was performed to assess the cover-
age level of these enhancer-associated marks in the three sets of 
CEBPA regions (Fig. 1A and fig. S1B). Quantification of H3K4me1 
(associated with an open chromatin structure) and H3K27ac (asso-
ciated with active regions) levels shows substantial decoration with 
both marks in the common regions and no difference between the 
Lp30 and WT conditions (Fig. 1, C and D). In comparison, p42-specific 
regions display an overall lower level of enhancer marks [P (H3K27ac 
common versus p42) = 2.9 × 10–151 and P (H3K4me1 common versus 
p42) = 4.6 × 10–164] and, moreover, a significant drop in the H3K27ac 
and H3K4me1 marks between WT and Lp30 L-GMPs, suggesting 
that CEBPA binding is required to maintain the activity levels of the 
p42 regions. In contrast, the p30-specific regions exhibit high H3K27ac 
levels in WT GMPs, which are further increased in Lp30 L-GMPs 
(Fig. 1, C and D). This demonstrates that p30-specific CEBPA binding 
is found primarily in regions that are already open (H3K4me1) and 
active (H3K27ac) in WT GMPs and become further activated fol-
lowing leukemic transformation.
CEBPA target enhancers can be subdivided into early (LSK; Lin–, 
Sca1+, Kit+ and preGM; pre–granulocyte-macrophage progenitors) 
or late (GMP and granulocyte) activity enhancers based on their 
histone mark patterns during normal hematopoiesis as defined previ-
ously (6). The p42 regions overlap more with late than with early 
enhancers in accordance with the classical role of CEBPA in granu-
lopoiesis (10), whereas p30 regions show no overlap preference (Fig. 1E).
Gene expression profiling by RNA sequencing (RNA-seq) showed 
a substantial number of deregulated genes (log2 fold change > 0.58, 
P < 0.05 by edgeR, see Materials and Methods) with higher (2342 genes) 
or lower (2469) expression in Lp30 L-GMPs compared to WT GMPs 
(Fig. 1F and data file S2). In line with a loss of transactivation activity 
as a consequence of the truncated trans-activation domain (TAD) 
in p30 (fig. S1C) (17, 18), genes associated with common regions are 
more frequently down-regulated (1600) than up-regulated (1191) 
when comparing the Lp30 L-GMPs to their GMP WT counterparts. 
For the p42 and p30 regions, gene expression changes are in accord-
ance with the differences in overall enhancer histone mark levels at 
these regions. Hence, p42 regions are preferentially associated with 
down-regulated genes (308 versus 102 up-regulated), while p30 regions 
are more associated with up-regulated genes (359 versus 253 down- 
regulated), comparing the Lp30 L-GMPs to WT GMPs (Fig. 1F). 
Together, gene expression and histone mark pattern changes indi-
cate that CEBPA predominantly acts as a transcriptional activator, 
both in the Lp30 and in the WT cells, in line with most previous 
studies on CEBPA in late granulopoiesis.
In conclusion, we identify genomic regions bound specifically by 
p30 in the leukemic condition. Binding of p30 at these regions leads 
to increases in enhancer mark levels and changes in gene expres-
sion, suggesting that p30 is initiating a unique transcriptional program, 
potentially influencing leukemogenesis.
Leukemia-specific CEBPA target enhancers are enriched 
for E-twenty-six (ETS) family motifs and low-affinity  
CEBPA sites
To elucidate the differential CEBPA binding and enhancer mark 
activity of the p30 and p42 isoforms, we examined the relative en-
richment of known TF binding motifs at p42- and p30-specific 
regions using the common regions as a reference. TF motifs enriched 
in p30 regions compared to common regions are binding sites recog-
nized by TFs belonging to either the CEBP or the ETS family (e.g., 
ELKs, ERG, ETSs, ETVs, GABP1, FEV, and FLI1) (Fig. 2A) (see data 
file S1 for the full list of motifs). Among the ETS factors, ERG, FLI1, 
and PU.1 belong to a core set of TFs previously shown to bind at a 
wide range of hematopoietic enhancers in the murine HPC-7 stem/
progenitor cell line (19). Using these data, we demonstrated that 
binding of the ETS factors was selectively depleted at p42-specific 
regions, and ERG in particular displayed a high degree of overlap 
with common and p30-specific regions (Fig. 2B). Moreover, and in 
contrast to FLI1 and PU.1, global quantitative proteomics analysis 
demonstrated that ERG was selectively up-regulated in Lp30 L-GMPs 
compared to WT GMPs, hinting at a role for ERG in binding of p30 
to the p30-specific regions (Fig. 2C and data file S3). Conversely, the 
sequences enriched at the p42 regions are binding sites for the basic 
region leucine zipper (bZip) domain–containing CEBPs, as well as 
the PAR bZip family members DBP, HLF, and TEF (Fig. 2A). Of 
these, several are expressed in WT GMPs, e.g., CEBPE, CEBPG, and 
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CEBPZ (protein), as well as Tef and Hlf (mRNA). Tef is up-regulated, 
while Hlf is strongly down-regulated in Lp30 L-GMPs (Fig. 2D and 
data file S2). Thus, some of the loss of CEBPA binding at p42-specific 
regions might be explained by the loss of cobinding with HLF, as 
this factor has some occupancy overlap with the p42-specific regions 
(fig. S2A). Of the CEBP family members, CEBPA itself was strongly 
up-regulated (Fig. 2, C and D, and data file S3), which is consistent 
with previous findings in both human and murine CEBPA mutant 
AML (11, 20). We validated these findings using quantitative reverse 
transcription polymerase chain reaction (RT-qPCR) (Cebpa; Fig. 2E) 
and Western blotting (CEBPA; Fig. 2F and fig. S2B).
To further probe the differential binding of the p30 and p42 CEBPA 
isoforms, we next compared the CEBPA motif scores (i.e., focusing 
only on bona fide CEBPA motifs) in each individual bound region 
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and found that, compared to the common regions, p42 regions, on 
average, harbor better matching motifs, while p30 regions display a lower 
average match score (Fig. 2G). Similarly, when we assess the CEBPA 
motif score distribution, CEBPA motifs associated with p30-specific 
regions are shifted toward low-scoring CEBPA motifs, compared to 
common and p42-specific regions (Fig. 2H), with both high- and 
low-scoring motifs conforming to CEBPA motifs (fig. S2C). These 
findings suggest that the increased CEBPA levels in Lp30 L-GMPs 
allow the p30 isoform to associate with low-affinity CEBPA sites.
Overall, our data indicate that CEBPA-p30–specific binding in 
Lp30 L-GMPs occurs at already active (H3K27ac marked) or at least 
open (H3K4me1 marked) enhancers. These enhancers are normally 
not bound by CEBPA in GMPs but are associated with other TFs such 
as ERG. We propose that increased levels of CEBPA in the Lp30 cells 
promote the binding of p30 to the low-affinity CEBPA motifs, leading 
to increased expression of a subset of associated genes.
Comparative analyses of murine and human CEBPA mutant 
AML pinpoints conserved transcriptional changes
We next set out to identify deregulated genes shared between human 
AML and the corresponding Lp30 mouse model, i.e., the shared core 
p30 leukemic transcriptional program, to identify gene expression 
CEBPA
Motif score
(−30,−10]
(−10,0]
(0,2]
(2,4]
(4,6]
(6,8]
(8,10]
0
25
50
75
100
D
en
si
ty
p42
Common
p30
A
E
F
G
H
WT GMPs
Lp30 L-GMPs
0.0
0.2
0.4
0.6
0.8
1.0
C
eb
pa
 e
xp
re
ss
io
n
n
o
rm
a
liz
ed
 to
 A
ct
g
1
***
B
p30
Common
p42
p30
Common
p42
p30
Common
p42
0
5
10
15
0
5
10
15
0
10
20
30
%
 o
ve
rla
p 
ER
G
%
 o
ve
rla
p 
FL
I1
%
 o
ve
rla
p 
PU
1
p42
p30
Hist.H3
WT
 GMPs 
Lp30 L-GMPs
5.0
7.5
10.0
12.5
M
at
ch
 s
co
re
 w
ith
 P
W
M
 (lo
g)
p42
Common
p30
**
**
D
**** ****
*
ns
0.05
0.06
ns
RN
As
eq
 T
PM
 va
lue
s 
****
**** ****
Lp30 L-GMPs
WT GMPs
Erg Fli1 Pu1
Cebpa
Cebpd
Cebpe
Cebpg
Cebpz
Hlf Tef
0
40
80
120
SPIB
SFPI1
FOS::JUN
FLI1
FEV
GABP1
ETV6
ETV5
ETV4
ETV1
ETS2
ETS1
ERG
ELK4
ELF5
ELF3
ELF1
DLX2
TEF
NFIL
HLF
DBP
CEBPG
CEBPE
CEBPD
CEBPB
CEBPA
p42
Common
p30
−1 10
ELK1
C
0
1.5 × 108
1.0 × 108
5.0 × 107
M
as
s-
sp
ec
 L
FQ
 va
lue
s Lp30 L-GMPs
WT GMPs
ERG
FLI1
PU1
CEBPA
CEBPD
CEBPE
CEBPG
CEBPZ
**
**
*
**
**
ns
*
ns
Fig. 2. Motif enrichment analysis of p42, common, and p30 CEBPA-bound regions. (A) TF motif enrichment analysis, combining results from three TF motif databases. 
The set of common regions is used as reference, and the relative enrichment z scores for p42 and p30 regions (compared to common) are displayed as shades of orange (enriched) 
or blue (depleted). (B) Percentages of CEBPA-bound regions overlapping with regions bound by ERG, FLI1, and PU1 in the HPC-7 cell line. (C) Proteomics quantification of 
TFs with enriched motifs, comparing FACS isolated WT GMPs and Lp30 L-GMPs (Limma multifactorial analysis, Benjamini-Hochberg corrected P value. *P ≤ 0.05; 
**P ≤ 0.01). (D) RNA-seq quantification of TF gene expression with enriched motifs, comparing WT GMPs and Lp30 L-GMPs (RNA-seq, *FDR ≤ 0.05; ****FDR ≤ 0.0001). (E) RT-qPCR 
quantification of Cebpa expression normalized to Actg1 (WT GMPs, n = 3; Lp30 L-GMPs, n = 7, Student’s t test. ***P < 0.001). (F) CEBPA Western blot using WT GMPs and 
Lp30 L-GMPs. The CEBPA and Histone H3 bands were obtained from the same blot incubated with different Abs. (G) All CEBPA motifs found in p42, common, and p30 
region sets tested for their match to the CEBPA consensus (Jasper DB. One-tailed Wilcoxon test. **P ≤ 0.001). (H) Frequencies of bins of CEBPA-consensus matching motifs 
in each region set.
 o
n
 August 27, 2019
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Jakobsen et al., Sci. Adv. 2019; 5 : eaaw4304     10 July 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 16
changes of potential clinical relevance. To this end, leukemic and 
normal GMPs from four patients with N/C-biallelic CEBPA mutant 
AML and two healthy volunteers, respectively, were isolated by 
FACS and subjected to RNA-seq (fig. S3A). Overall, fewer genes are 
deregulated (log2 fold change > 0.58, P < 0.05, edgeR, see Materials 
and Methods) in the human leukemic cells as compared to those of 
mice (data file S2), likely reflecting a higher level of biological vari-
ation in the human samples. More genes are down-regulated (2064) 
than up-regulated (1491) when comparing L-GMPs to normal 
GMPs (Fig. 3A).
Gene Ontology (GO) analyses revealed enrichment of many 
shared categories between human and mouse AML-associated gene 
expression changes (data file S4). Examples of categories signifi-
cantly associated with up-regulated genes shared between the two 
species include “nucleosome core,” “focal adhesion,” “immunity,” 
“apoptosis,” and “negative regulation of cell proliferation.” Similarly, 
many categories were shared between human and mouse down-regulated 
genes, including “cytoskeleton,” “cell cycle,” “cell junction”/“focal 
adhesion,” “transcription,” and “DNA damage” (Fig. 3B and fig. S3B).
To pinpoint conserved changes of individual genes, we generated 
a stringently filtered shortlist of genes for which a direct human or 
mouse ortholog could be identified and counted genes with aligned 
up- or down-regulation [using a cutoff of false discovery rate 
(FDR) < 0.01 for both edgeR and DEseq] (data file S2). Of the 415 (human) 
and 1778 (mouse) shortlisted genes, 102 were found to be regulated 
in the same direction, which corresponds to threefold more than 
expected by random distribution (P < 0.0005, Fisher’s exact test) (Fig. 3C). 
Hence, these 102 genes constitute the core transcriptional program of 
CEBPA mutant AML and further demonstrate that the Lp30 mouse 
model mirrors key features of the corresponding human disease.
We next sorted the 102 genes associated with the CEBPA mutant 
transcriptional program based on expression fold changes in both 
species (Fig. 3D, left) and found that most were down-regulated 
(82 genes), while only 20 genes were up-regulated in Lp30 L-GMPs 
compared to normal GMPs. Notably, Gene Set Enrichment Analysis 
(GSEA) showed a strong overrepresentation of the 20 up-regulated 
genes and underrepresentation of the 82 down-regulated genes in 
biallelic CEBPA AML versus all other AMLs in the The Cancer 
Genome Atlas (TCGA) dataset (fig. S3C), supporting the notion of 
a subtype-specific core genetic program in human AML.
Normalizing expression changes individually for human and mouse 
samples (Fig. 3D, right), we found that only the top three genes, 
ARPP21/Arpp1, NT5E/Nt5e, and ITGAX/Itgax, were up-regulated 
from almost undetectable levels in healthy cells to high expression 
in leukemic cells derived from both species (data file S2). Of these, 
only Nt5e was significantly up-regulated at the protein level (NT5E/
CD73) (Fig. 3E), while ARRP21 was not found by the proteomics 
analysis and ITGAX was not up-regulated (Fig. 3E and data file S3).
In summary, we have defined cross-species conserved core 
expressional changes induced by the CEBPA-p30 AML driver. 
Up-regulated genes, encoding potentially druggable proteins, were 
limited to a narrow set, in which Nt5e is an interesting candidate.
A leukemia-specific CEBPA-p30–bound enhancer controls 
Nt5e transcription
Nt5e encodes NT5E, ecto–5′-nucleotidase (aka CD73), an ectoenzyme 
that catalyzes the rate-limiting step of AMP to adenosine conversion. 
CD73 facilitates progression in several cancer types via (i) evasion 
of anti-tumor immune responses (21, 22) and (ii) adenosine-mediated 
inhibition of apoptosis and promotion of proliferation of the tumor 
cells (23, 24). Our demonstration of the conserved up-regulation of 
CD73 in p30-driven AML is therefore intriguing, and we sought to 
explore the connection further.
First, we validated the AML-specific expression of Nt5e mRNA 
and CD73 protein by independent methods in the Lp30 mouse 
model (Fig. 4, A and B). Having established a leukemia-specific ex-
pression of Nt5e, we investigated whether the aberrant expression 
of CEBPA-p30 in leukemic cells directly affects Nt5e levels. Scru-
tinizing the ChIP-seq data, we found that the p30-specific regions 
included a position 40 kb upstream of the Nt5e transcription start 
site (TSS), displaying clear CEBPA binding and enhancer-associated 
marks (H3K4me1 and H3K27ac) exclusively in the Lp30 cells, indi-
cative of a leukemia-specific enhancer (Fig. 4C). Notably, this putative 
regulatory region is not decorated by H3K4me1 or H3K27ac histone 
marks at the granulocyte stage, suggesting that the enhancer mark is 
not due to premature differentiation of Lp30 L-GMPs (fig. S4A).
To investigate whether the putative −40-kb enhancer could reg-
ulate Nt5e expression, we first examined whether this region physi-
cally interacted with the Nt5e TSS using chromosome conformation 
capture (3C) with qPCR. Of seven tested regions spanning 50 kb 
upstream of Nt5e, we found two bordering the enhancer region inter-
acting significantly with the TSS when comparing Lp30 L-GMPs to 
a cKit-enriched bone marrow (BM) control population, consistent 
with a direct physical contact between the −40-kb region and the 
Nt5e TSS (Fig. 4C, middle). We then applied CRISPR interference 
(CRISPRi) to assess the functional role of the −40-kb enhancer (25). 
To this end, we targeted two control positions (−112 and −15 kb, 
located distally from and in between the enhancer and TSS, respectively) 
and two enhancer positions, as well as the TSS with guide RNAs 
(gRNAs). This resulted in a significant reduction of Nt5e expression 
for enhancer-directed gRNAs equivalent to TSS targeting, compared 
to the controls (Fig. 4C, bottom). In contrast, no neighboring genes 
were significantly affected (fig. S4B). Last, we cloned the −40-kb region 
to a luciferase reporter vector and observed a small but significant 
induction of expression upon cotransfection with either CEBPA-p42 
or the mutant p30 isoform (Fig. 4D). This supports the region’s 
potential as a CEBPA targeted enhancer, activatable by either isoform 
when present at sufficient levels.
In combination, these data indicate that, in the Lp30 mouse model 
of CEBPA mutant AML, elevated levels of the p30 isoform directly 
drive expression of Nt5e. This is accomplished via a 40-kb upstream 
enhancer active exclusively in the malignant cells.
NT5E is overexpressed in CEBPA mutant AML patient 
samples and controlled by a CEBPA targeted enhancer
To test the potential clinical relevance of our findings in the Lp30 
mouse model, we next wanted to extend them to human AML. To 
this end, we first carried out RT-qPCR and confirmed the high ex-
pression of NT5E found in our human RNA-seq data along with 
elevated levels of CEBPA (Fig. 5, A and B). Moreover, using flow cyto-
metric analysis, we observed increased frequencies of GMP-resembling 
cells within the CD3− CD19− fraction (devoid of residual normal 
lymphocytes) of the CD73+ population in patients with AML with 
biallelic CEBPA mutations (fig. S5A). These findings were further 
corroborated by analysis of three publicly available AML gene ex-
pression datasets, all demonstrating the high expression of CEBPA 
and NT5E in CEBPA mutant AML compared to other normal karyo-
type subtypes (Fig. 5C). The difference between CEBPA mutant and 
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other normal karyotype samples was most pronounced in the TCGA 
data, likely due to the lack of distinction between monoallelic and 
biallelic CEBPA mutant AMLs in the two older datasets (26, 27). 
Last, we used RT-qPCR to test the expression of NT5E in a panel of 
defined AML subtype and healthy volunteer samples. Notably, we found 
that, apart from biallelic CEBPA mutant AML, NT5E expression was 
only consistently up-regulated in INV(16) AML (Fig. 5B). Analysis 
of a previously generated ChIP-seq dataset demonstrated that the 
CBFB- MYH11 fusion protein, associated with INV(16) AML, is 
located right at the NT5E promoter (fig. S5B) (28). These findings 
strongly suggest that NT5E/CD73 is specifically up-regulated by two 
leukemic driver mutations in their respective AML subtypes.
To elucidate the regulation of NT5E expression in human biallelic 
CEBPA mutant AML, we performed ChIP-seq for the H3K27ac histone 
mark on sorted GMP samples from either bi- or monoallelic CEBPA 
mutant AML patients or from healthy volunteers. Notably, a region 
48 kb upstream of the human NT5E TSS displayed K27 acetylation 
in biallelic CEBPA mutant cells but neither in the monoallelic AML 
sample nor in healthy cells (Fig. 5D). Comparison with an external 
H3K4me1 and H3K27ac dataset from CD34+ hematopoietic stem 
and progenitor cells (29) revealed enrichment for H3K4me1, but 
not for H3K27ac. This indicates that the −48-kb region is in an open 
but inactive state at the earliest phase of hematopoietic differentiation. 
Inspection of a comprehensive, human pan-hematopoiesis HiC study 
revealed that this region physically associates with the NT5E TSS in 
CD8+ T cells (Fig. 5D, black and red bars) (30). Another publicly 
available ChIP-seq study showed the region to be marked by both 
H3K4me1 and H3K27ac in a similar T cell subset (Fig. 5D) (31), 
suggesting that, in these NT5E-expressing T cells, the region functions 
as an active enhancer driving NT5E transcription. Last, the −48-kb 
region gave rise to a small but significant increase in reporter ac-
tivity in response to either p42 or p30 expression (Fig. 5E), indi-
cating that CEBPA is able to function as a trans-activator at this 
region.
In short, our data show that both CEBPA and NT5E are specifically 
overexpressed in human biallelic CEBPA mutant AML. Our identi-
fication of an AML-specific −48-kb enhancer that can be activated 
by CEBPA suggests that CEBPA directly drives overexpression of 
NT5E in human CEBPA mutant leukemia, in line with the mechanism 
observed in the mouse model.
Down-regulation of Nt5e delays leukemia  
development in vivo
We next wanted to assess whether Nt5e played a tumor-promoting 
role in CEBPA mutant AML, and to this end, we applied short hairpin 
RNA (shRNA)–mediated knockdown of the gene (Fig. 6A). Lp30 cells 
transduced with retroviruses encoding either a scrambled (control) 
shRNA or one of two individual shRNAs targeting Nt5e along with 
a green fluorescent protein (GFP) marker were used for a competitive 
BM transplantation (BMT) assay (Fig. 6B). BM cells were harvested 
4 weeks after BMT, and the GFP/YFP (yellow fluorescent protein) 
ratio of the leukemic cells was analyzed by flow cytometry analysis 
(Fig. 6C). Nt5e knockdown leukemic cells were efficiently outcompeted 
by competitor cells in comparison to the scrambled mix, thus estab-
lishing a tumor-promoting role of Nt5e in leukemia progression 
in vivo (Fig. 6D).
To further assess the effect of Nt5e knockdown on disease pro-
gression, we carried out a survival analysis on recipients transplanted 
with AML cells transduced with shNt5e or scrambled control. In ac-
cordance with the competitive assays, we found that shRNA-mediated 
Nt5e knockdown led to a significantly increased latency time compared 
to the scrambled control, with a median survival of 51.5 days for the 
scrambled control and 66.5 and 71 days for each of the shRNAs (Fig. 6E).
To rule out the possibility of off-target effects of the shRNAs, 
and to validate the ability of the enhancer to regulate Nt5e expression 
in vivo, we applied CRISPRi using gRNA constructs targeting either 
the Nt5e TSS or the −40-kb enhancer for transcriptional repression 
(Fig. 4C, bottom). Sublethally irradiated mice were transplanted with 
sorted Lp30 cells double positive for the KRAB-dCas9-mCherry 
and sgRNA-GFP expression vectors. Targeting either the Nt5e TSS 
or the −40-kb enhancer for transcriptional repression significantly 
increased survival of recipient mice compared to targeting the 
−112-kb control region (Fig. 6F).
Collectively, these results establish Nt5e as a critical factor for 
tumor progression in Lp30 AML. Importantly, our data also pro-
vide functional validation of the –40-kb Nt5e enhancer in vivo.
CD73 promotes tumor-protective adenosinergic autocrine 
signaling and is a potential therapeutic target in AML
Up-regulation of CD73 can cause an increased generation of extra-
cellular adenosine. Accumulation of adenosine in the extracellular 
space signals through one or more of the four adenosine receptors: 
A1R, A2AR, A2BR, or A3R encoded by Adora1, Adora2a, Adora2b, 
and Adora3 (32). RT-qPCR analysis of Lp30 and WT cell samples 
showed a specific and selective high expression of Adora2a, in com-
parison to Adora1, Adora2b, and Adora3 in the Lp30 cells (Fig. 6G). 
Human biallelic CEBPA mutant AML also displays ADORA2A, 
ADORA2B, and ADORA3 expression, again with ADORA2A being 
the highest, which is paralleled in human INV(16) AML (fig. S6A). 
In a cancer setting, adenosine signaling, in particular, via the A2AR, 
may contribute to tumor progression by modulating inflammatory 
processes, promoting proliferation, and inhibiting apoptosis of the 
cancer cells, mostly via activation of the intracellular cyclic adeno-
sine monophosphate (cAMP) pathway (33).
To examine expression changes caused by knockdown of Nt5e in 
the Lp30 cells, we performed RNA-seq analysis on Lp30 leukemic cells 
transduced with shNt5e or scrambled control (data file S5). To test 
the hypothesis that adenosine generated by CD73 can have an auto- 
or paracrine effect on the leukemic cells through activation of A2AR, 
we curated a negative A2AR signature of downstream targets di-
rectly suppressed by A2AR signaling and calculated the signature 
enrichment alongside GO signatures identified using GSEA (data 
file S7). The negative A2AR signaling signature had the highest fold 
change between control and Nt5e knockdown Lp30 cells, followed 
by signatures associated with immune activation, responses that are 
affected by adenosine/cAMP signaling as well (Fig. 6H) (34). This 
suggests that targets normally repressed in Lp30 cell by A2AR sig-
naling are indeed up-regulated by Nt5e knockdown, which sup-
ports the notion of an adenosinergic autocrine loop of signaling, 
promoted by CD73 in the Lp30 cells. Further, we queried the TCGA 
AML dataset by GSEA and found the A2A signature genes to be 
repressed in the biallelic CEBPA-mutated subtype versus all other 
subtypes (Fig.  6I), supporting the existence of subtype-specific 
signaling.
To directly assess the functional effect of A2AR signaling on cell 
growth, we measured the proliferation rates of Lp30 cells subjected 
to a specific A2AR inhibitor, SCH-58261. Cells treated with increasing 
concentrations of the inhibitor showed a dose-dependent decrease 
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in growth rates (fig. S6, B and C). In comparison, murine leukemic 
Inv(16) cells with low A2AR expression were not affected, demon-
strating the requirement for A2AR (fig. S6, D and E). Analyses of 
A2AR inhibitor–treated Lp30 cells revealed a significant >2-fold 
decrease of cells in the S-G2-M phase (fig. S6, F, G, and H) and a 
marked increase of apoptotic cells (sub-G1 or annexin V marked) 
compared to the control (fig. S6, G and I).
Studies on solid cancer models have demonstrated anti-tumor 
effects of inhibiting CD73 activity with specific blocking monoclonal 
Abs (mAb) or using genetic knockdown (35–39). Expression of A2AR 
Fig. 5. Up-regulation of NT5E in human AML samples with biallelic CEBPA mutations. (A) RT-qPCR quantification of CEBPA mRNA in sorted GMPs from healthy individuals 
as well as patients with AML with monoallelic and biallelic CEBPA mutations. Normalized to POL2 and H6PD (n = 5, 4, and 4, mean ± SEM). (B) RT-qPCR quantification of NT5E ex-
pression levels in sorted GMPs from healthy individuals and patients with AML with the indicated mutational status. Normalized to POL2 and H6PD (n = 8, 3, 4, 6, 6, 9, 3, 3, 4, 4, 1, 
6, 22, 7, 8, and 5, mean ± SEM). Statistical significance was assessed using one-way ANOVA with Dunnett’s correction for (A) and (B), where the mean of each group was compared 
to the WT-GMP group. (C) Normalized expression of CEBPA and NT5E in datasets extracted from the cBioPortal (TCGA data, RNA-seq) and Leukemia Gene Atlas (expression array) 
databases (mean ± SD). For Kohlmann and Verhaak datasets, the monoallelic and biallelic CEBPA-mutated subtypes are binned as one group, and for TCGA data, the biallelic 
subtype is separate. (D) Top: ChIP-seq analysis on GMPs from healthy individuals and L-GMPs from patients with AML with monoallelic and biallelic CEBPA mutations showing a 
putative enhancer located 48 kb upstream of the human NT5E gene. Center: ChIP-seq tracks from CD34+ hematopoietic progenitor cells. Bottom: Publicly available Hi-C data in black 
and red bars (30) and ChIP-seq tracks (31) from the same region in CD8 T cells. (E) Dual luciferase assay assessing p42- or p30-mediated trans-activation of the −48-kb enhancer 
cloned upstream of a minimal promoter compared to an empty vector control (n = 3, mean ± SEM, Student’s t test). For all panels, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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Fig. 6. Effect of Nt5e KD on in vivo AML progression and identification of CD73 tumor-protective adenosinergic signaling as a potential therapeutic target. 
(A) Nt5e knockdown efficiency; RT-qPCR quantification of Nt5e normalized to Actg1. GFP+ sorted Lp30 cells transduced with shNt5e or scrambled control (n = 3, mean ± SD). 
(B) Schematic outline of competitive BM transplant experiment. (C) Representative FACSs of Lp30 cells transduced with shRNA targeting Nt5e or scrambled control at the 
input and output time points. (D) Target-to-competitor (GFP/YFP) ratio of Lp30 cells transduced with shRNA targeting Nt5e or scrambled control after BMT and 4 weeks 
of leukemia progression. Ratio was normalized to input cells. (n = 4, mean ± SD). (E) Survival of recipient mice transplanted with 2.5 × 104 GFP+-sorted Lp30 cells transduced 
with shNt5e or scrambled control (n = 8). (F) Survival of recipient mice transplanted with 5 × 103 cells double positive for KRAB-dCas9-mCherry and sgRNA-GFP targeting 
Nt5e TSS, a putative enhancer (−40 kb), or a negative upstream region (−100 kb) (n = 7 and 8). (G) RT-qPCR quantification of Adora1, Adora2a, Adora2b, and Adora3 in Lp30 
L-GMP and WT-GMP cells, displayed as ratios to levels in whole BM cells. Normalized for each cell type to Actg1 (wBM, n = 3; GMPs, n = 5 to 6). (H) Signatures enriched in 
both Nt5e knockdown groups in vivo compared to scrambled control based on RNA-seq (Scr, n = 3; shNt5e #1, n = 3; shNt5e #2, n = 2). Color indicates log2 fold change 
(red) and P value (purple) for each signature. See data file S6 for full list. (I) Plot and statistical values from GSEA testing genes of the negative A2A signature in biallelic 
CEBPA-mutated AML versus all other AML subtypes; TCGA AML expression dataset. (J) Survival of recipient mice transplanted with 100 freshly harvested Lp30 cells. Mice 
were injected intraperitoneally with mock, A2ARi (SCH-58261, 20 g), anti-CD73 (2C5-IgG2a, 100 g), and control-Ig (NIP228-IgG2a, 100 g) in combinations as indicated. 
Treatments were twice weekly from day 1 until the first mouse was euthanized, as specified on the graph. (K) Model of Nt5e differential leukemia-specific expression as a 
consequence of elevated CEBPA-p30, leading to engagement of the Nt5e AML enhancer. Blue ovals represent CEBPA-p42, and red ovals represent CEBPA-p30 monomers. 
Bottom: Half blue ovals represent CEBPA-p42 mutated in the DNA-binding domain, often present in human biallelic CEBPA-mutated AML. Statistics were determined by 
Student’s two-tailed t test (two groups) or one-way ANOVA corrected for multiple comparisons (Dunnett’s correction) between control and treatment groups (three or 
more groups) or log-rank test (survival). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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on myeloid cells is required for efficacy of CD73 inhibition (40). In 
addition, an additive effect of combining CD73 mAb with an A2AR 
inhibitor has been demonstrated in a breast cancer model (39). To test 
whether interruption of adenosine signaling in the Lp30 cells could 
halt AML progression in vivo, we transplanted recipient mice with 
Lp30 cells and treated them with either a CD73 mAb or the SCH-
58261 A2AR inhibitor, or the combination of the two. Treatment 
with any of the agents as a monotherapy showed a trend toward 
increased survival time (median survival of 62 and 59.5 days for mAb 
or A2ARi, respectively), whereas the combination caused a signifi-
cant increase in median survival time (69 days) over both immuno-
globulin G (IgG) + Mock (58 days) and any of the treatments alone 
(Fig. 6J), supporting a favorable additive effect on survival by blocking 
different nodes of the adenosine signaling pathway.
Together, these results support the notion of leukemia-specific 
CD73-mediated production of adenosine to signal via A2AR, pro-
moting proliferation and preventing apoptosis in a cell-autonomous 
manner. This tumor-protective autocrine signaling loop is likely 
initiated by the AML-specific CEBPA-p30 binding and activation 
of the novel distal enhancer of Nt5e/NT5E (Fig. 6K). The in vivo 
results point toward the potential therapeutic benefit of targeting 
the CD73/A2AR axis, thereby inhibiting the adenosinergic pathway.
DISCUSSION
Biallelic CEBPA mutant AML constitutes a distinct genetic and mo-
lecular subgroup within AML, elicited by the isoform shift from 
essentially p42-restricted expression to exclusive functional usage 
of the CEBPA-p30 AML driver (10). Characterization of the func-
tional consequences of such oncogenic drivers is critical to develop 
new treatment regimens for AML subtypes, classically treated with 
nonspecific, cytotoxic chemotherapeutics. In this study, we found 
that differential chromatin occupancy of CEBPA directly influences 
transcriptional output in the leukemic condition. Moreover, we iden-
tified critical, tumor-promoting genes driven directly by the p30 isoform, 
at least partially explaining the underlying causal role of this isoform 
in leukemogenesis. To our knowledge, this is the first time that such 
a mechanism has been demonstrated for an oncogenic TF variant. 
Last, we describe the p30-dependent, and thus CEBPA biallelic-specific, 
up-regulation of Nt5e as a tumor-promoting factor and a potential 
therapeutic target.
Despite a high degree of shared specificity of p30/p30 homodimers 
in L-GMPs and p42/p42 homodimers (as well as small amounts of 
p42/p30 and p30/p30 dimers) in WT GMPs, a substantial number 
of binding sites showed differential binding between the two isoforms. 
Our computational motif enrichment search revealed that the 
p30-specific regions harbored relatively more low-affinity CEBPA 
binding sites than their shared and p42-specific counterparts. We 
suggest that, to a large extent, this can be explained by the increased 
expression of CEBPA in L-GMPs, which would allow CEBPA-p30 
to associate with low-affinity binding sites. In addition, one could 
hypothesize that the loss and gain of alternative CEBPA interaction 
partners might influence site specificity. Of note, we observe that Hlf 
levels were reduced, while Erg display increased expression in the 
leukemic context. Concordantly, we found a substantial overlap be-
tween p42- and p30-specific binding and cognate binding sites for 
HLF and ERG, respectively. Further, we observed that p30-specific 
regions are defined by active enhancer marks, suggesting that p30 
mainly binds chromatin that is already open. Conversely, p42-specific 
regions in WT GMPs displayed a relatively low openness as defined 
by H3K4me1 coverage, suggesting that these regions depend on the 
“pioneering” activity of full-length CEBPA (6, 41) and that p30 does 
not retain this activity. This is emphasized by the fact that p42 binding 
overlaps relatively more with late enhancers, which depend on the 
pioneering capacity of this isoform (6). As for the correlation be-
tween CEBPA binding and gene expression changes, the common 
regions were generally associated with genes down-regulated in L-GMPs. 
This is probably accounted for by the absence of the N-terminal 
TAD1 in the p30 isoform, which has previously been shown to have 
the major trans-activation potential of the protein. Conversely, 
p30-specific binding is associated with leukemia-specific increases 
in gene expression, underscoring that the TAD2 is sufficient (albeit 
less efficient) for gene activation, potentially also by cooperating with 
other TFs, like ERG. Collectively, our analyses demonstrate that 
CEBPA-p30 controls an AML-specific transcriptional program through 
novel binding at already established enhancers, induced, in part, by 
the increased expression of the p30 isoform, and that modulation of 
CEBPA binding may potentially be influenced by other TFs such as 
ERG and HLF.
Previous work has identified Cebpg and Sox4 as critical down-
stream targets of CEBPA in CEBPA silenced/CEBPA mutant AML, 
respectively (15, 16). Both proteins are normally repressed by CEBPA 
and up-regulated in its absence and, in the case of SOX4, up-regulated 
by the expression of the p30 isoform as well. In line with this, we 
found that both p42 and p30 bind the promoters of both genes and 
that SOX4 is up-regulated in Lp30 L-GMPs (data not shown). One 
possible explanation for the derepression of these genes following 
the p42 to p30 isoform switch could be that repression depends on 
the previously reported selective association of p42 with HDAC1 
and HDAC2 (42).
Overall, our data, together with previous studies, suggest that the 
isoform switch from p42 to p30 expression drives an AML-specific 
transcriptional program via several mechanisms, including (i) loss of 
CEBPA-driven gene expression at p42-specific loci, (ii) loss of 
p42-mediated repression at common sites, (iii) loss of transcrip-
tional activity at common regions due to reduced transcriptional 
activity of the p30 isoform, and (iv) activation of already established 
enhancers via p30 binding to low-affinity sites mediated by its in-
creased expression and potentially also by ETS factors such as ERG.
Although targeting of, SOX4 and CEBPG may have a potential 
benefit in CEBPA mutant AML, TFs are generally not considered as 
good drug targets as cell-surface proteins or proteins harboring enzy-
matic activities such as kinases and epigenetic regulators. Here, we 
identified Nt5e as belonging to a transcriptional program driven by 
the p42 to p30 isoform switch in CEBPA mutant AML. We found 
Nt5e expression to be regulated by a p30-bound leukemic-specific 
enhancer in a manner that appears to be conserved across human 
and murine AML. Apart from CEBPA mutant AML, deregulated 
expression of NT5E was only consistently observed in INV16 AML, 
where the CBFB-MYH11 fusion protein locates directly to the promoter 
of NT5E and likely drives its expression. This demonstrates that 
NT5E up-regulation is tightly associated with specific oncogenic 
drivers. Down-regulation of Nt5e either by shRNAs or through 
CRISPRi using gRNAs targeting the TSS or the p30-bound −40-kb 
enhancer demonstrated a key role for CD73 as a tumor-promoting 
factor in CEBPA mutant AML.
CD73, together with CD39, catalyzes the formation of free ade-
nosine on the surface of lymphocytes, endothelial cells, and a large 
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subset of primary tumors (22). By shifting the balance between the 
immune-activating ATP and immune-suppressing adenosine, CD73 
has been proposed to protect cancer cells against the host immune 
system (21, 22). We tested this concept for the Lp30 AML model by 
comparing the effect of Nt5e knockdown in immunocompromised 
NSG mice versus C57BL/6 mice or following T cell depletion. How-
ever, in neither case did a reduction in the host immune system in-
terfere with the tumor-promoting effect of CD73 (data not shown), 
suggesting that CD73, in CEBPA mutant AML, protects tumor cells 
via another mechanism. Free adenosine may also act on tumor cells 
in a paracrine/autocrine manner via the adenosine receptors (33). 
In line with this, we found that treatment of Lp30 cells in vitro with 
an A2AR receptor antagonist halted cell cycle progression and in-
duced apoptosis. Moreover, we found that down-regulation of Nt5e 
promoted the derepression of genes, which are normally inhibited 
by the stimulatory action of A2AR on the adenyl cyclase, one of its 
downstream targets. Thus, our observations are consistent with a 
mechanism where CD73-dependent adenosine acts on A2AR to 
sustain leukemic cell growth and protect against apoptosis, paralleling 
earlier reports using a model of chronic lymphocytic leukemia (24).
To test the clinical potential of targeting the CD73-A2AR 
adenosinergic pathway, we used a combined CD73 Ab-mediated 
blocking/A2AR inhibition strategy and observed a significant in-
crease in survival of mice transplanted with Lp30 AML cells. The 
lack of pronounced efficacy of CD73 or A2AR targeted monotherapies 
has also been observed in solid tumor models and may involve 
pharmacokinetics issues of the CD73 Ab, which is optimized for 
human use (39, 43). We also note that the Ab isotype is an important 
parameter in our setting, as only the IgG2A and not the IgG1 isotype 
displayed therapeutic benefit (data not shown), perhaps reflecting the 
higher FcR binding capacity of the former. Similar findings have 
been made in the context of solid cancers (39).
In conclusion, our work provides novel insights on how an iso-
form switch in a key myeloid TF drives a leukemic-specific tran-
scriptional program, ultimately resulting in AML. We furthermore 
identify CD73 and A2AR as potential targets in biallelic CEBPA 
mutant AML via their ability to stimulate autocrine adenosinergic 
signaling. This contrasts observations in solid cancers, where CD73- 
mediated suppression of the adaptive immune system seems to be 
the main function of CD73 as a tumor-promoting factor (35, 36, 44), 
perhaps reflecting different physical properties of leukemic versus 
solid cancer niches. Currently, a number of agents targeting CD73 
and the adenosinergic pathway are being evaluated for their efficacy 
against a variety of solid cancers in early clinical trials, either as single 
agents or in combination with immune modulatory therapies such 
as anti-PD1 or anti-PDL1 (45). Another intriguing possibility is the 
combination with Janus kinase inhibitors, shown recently to be a 
potential CEBPA mutant targeted therapy (46). On the basis of the 
findings in the present work, we suggest that such emerging treat-
ment strategies should also be evaluated in the context of CEBPA 
mutant AML.
MATERIALS AND METHODS
Experimental design
To identify CEBPA-bound putative enhancers specific for CEBPA 
mutant AML, we performed microscale, in vivo ChIP-seq on sorted 
leukemic GMPs and their WT counterparts. RNA-seq was carried 
out to identify gene expression changes in human CEBPA mutant 
AML and the corresponding CebpaLp30 mouse model, leading to the 
identification of Nt5e, encoding CD73, as a cross-species AML gene. 
Functional validation of CD73 as a druggable tumor-promoting 
factor was carried out by shRNA or dCas9-KRAB–mediated KD or 
pharmacological inhibition followed by BMT.
BMT, mouse
All BMTs were carried out on sublethally irradiated 10- to 15-week-
old female B6-SJL recipients by intravenous tail vein injections. For a 
detailed description of different experimental setups, see Supplemen-
tary Materials and Methods. The CebpaLp30 mice were described in 
(11). All mouse experiments were conducted according to protocols 
approved by the Danish Animal Ethical Committee (permission 
#2013-15-2934-00780), with regard to the three R’s (refine, reduce, 
and replace) of animal experiments. Animals were housed in indi-
vidually ventilated cages, and all experiments were carried out under 
supervision of veterinarians of the Department of Molecular Medicine, 
University of Copenhagen.
Patients with AML and healthy controls, BM collection
BM cells were aspirated from the posterior iliac crest of healthy subjects 
and patients with de novo AML before treatment. This study was 
performed in accordance with the Declaration of Helsinki under 
the following ethical approvals: Copenhagen, H-15004577; Aarhus, 
M-20070171; London, 10/H0704/65-006650QM; and Ulm, 148/10.
Primary cultures and cell lines
Lp30 cells were generated by serial BMT/expansion of BM cells 
from leukemic primary CebpaLp30 mice. A pool of BM cells from 
tertiary expansions were used for both in vitro and in vivo experi-
ments. BM cells were harvested from femur, tibia, and iliac bones; 
crushed; washed; pooled; and frozen in vials.
For in vitro proliferation, cell cycle, and apoptosis assays, Lp30 cells 
(female) were grown in R20/20 media: RPMI 1640 medium (Life 
Technologies) supplemented with 20% WEHI conditioned media, 
20% fetal bovine serum (FBS), 1% penicillin/streptomycin (Pen/Strep), 
and cytokines (PeproTech): stem cell factor (SCF) (20 ng/ml) and 
hIL-6 (10 ng/ml). A2AR inhibitor (SCH58264, Sigma-Aldrich) was 
added from stock (5 mg/ml) in dimethyl sulfoxide (DMSO) to 30, 
10, or 3 M, and DMSO volume was normalized/added as mock.
BM cells from recipients transplanted with donor BM cells from 
Cbfb-MYH11 and KIT D816 mutant mice [Cbfb+/56m; Tg(Mx1-Cre)/
KITD816Y/V] [referred to as Inv(16) cells] (47) were grown in x-vivo 
complete media: X-VIVO 15 with gentamicin (Lonza), supplemented 
with 10% bovine serum albumin (BSA) (Stem Cell Technologies), 
0.1 mM -mercaptoethanol (Sigma-Aldrich), 1% l-glutamine (Gibco), 
1% Pen/Strep, and cytokines (PeproTech): mSCF (50 ng/ml), hIL-6 
(50 ng/ml), mIL-3 (10 ng/ml), and GM-CSF (10 ng/ml). Phoenix and 
HEK293T (human embryonic kidney line, female) cells were cultured 
in DMEM (Life Technologies) + 10% FBS and 1% Pen/Strep.
All cell cultures were mycoplasma-tested before freezing and never 
kept in culture for more than 3 months after rethawing. Phoenix 
and HEK293T cells were the only commercially available cell lines 
used, and virus production served as authentication of these cell lines.
Proliferation assays [Lp30 and Inv(16) cells]
Cells were plated at equal concentrations with varying concentra-
tions of the inhibitor and in triplicate wells. Cells were counted, the 
concentration was calculated every second/third day, and the cells 
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were replated at even cell concentrations. A growth curve was plotted 
for cumulative growth according to the dilution at each time point. 
Doubling time was calculated from fitted semi-logarithmic slope 
(Nonlin). Fit using least squares in GraphPad Prism software by 
log2/slope and Student’s two-tailed t test was used to test for signif-
icance. For cell cycle assays (Lp30 cells), cells were plated with 30 M 
inhibitor or DMSO for 24 hours. Cells were harvested, and an equal 
number of cells were fixed in 2% paraformaldehyde, permeabilized in 
0.1% saponin, stained with 4′,6-diamidino-2-phenylindole (DAPI), and 
analyzed by flow cytometry (LSR-II, BD Biosciences). For apoptosis 
assay (Lp30 cells), cells were plated with 30 M inhibitor or DMSO for 
72 hours, harvested, washed and stained using a PE-annexin V kit (BD 
Biosciences), and analyzed by flow cytometry (Accuri, BD Biosciences). 
All flow cytometry analyses were run with FlowJo software V.10.
Retro- and lentiviral transductions
sgRNA nucleotides were cloned into pLKO5-sgRNA-EFS-GFP (Addgene) 
as described in (48) with Bsm BI digestion. pLKO5-sgRNA-EFS-GFP 
and pHR-SFFV-KRAB-dCas9-P2A-mCherry (Addgene) were used 
for lentiviral supernatant production by transfection of HEK cells.
shRNA-mir oligonucleotides were cloned into the pMSCV-
LTRmiR30-SV40-GFP vector using Eco RI restriction digest. Retroviral 
supernatant was produced by transfection of Phoenix-ECO cells.
Expanded, tertiary Lp30 cell vials were thawed and cultured in 
x-vivo complete media. One day after thawing, cells were transduced 
twice on two consecutive days by 50-min retro- or lentivirus spin-
oculation (2000g, 32°C) on RetroNectin (Takara Bio)–treated and 
2% BSA (STEMCELL Technologies)–blocked wells, and cells were 
plated subsequently at 3 × 105 cells per milliliter of X-VIVOTM com-
plete media. For analysis after transduction, cells were resuspended 
in phosphate-buffered saline (PBS) + 3% fetal calf serum.
Flow cytometry
Analytical stainings were assessed on an LSRII, whereas cell sorting was 
carried out on either an Aria I or an Aria III (all instruments were from 
Becton Dickinson). Detailed descriptions of all stainings and gating 
strategies are provided in Supplementary Materials and Methods.
Western blotting
Flow cytometry–sorted GMPs (see above) from leukemic Lp30 and 
WT mice, corresponding to approximately 10,000 cells for each sample, 
were boiled in SDS-loading buffer for 5 min, subjected to nucleic 
acid degradation by Benzonase (E1014-5KU, Sigma-Aldrich) for 
20 min on ice, and spun for 20 min at 20,000g. Material was size- 
separated using NuPAGE precast 4 to 12% Bis-tris gels (Invitrogen). 
The Cell Signaling protocol (www.cellsignal.com/support/protocols/
western.html) was used for blotting. ImageJ was used for quantifi-
cations using program guidelines (http://rsb.info.nih.gov/ij/). CEBPA 
Ab [at 1:1000 dilution in 5% (w/v) BSA, 1 hour at room temperature] 
corresponds to the one used for ChIP (clone 14AA, sc-61, Santa Cruz 
Biotechnology), and loading control was anti-Histone H3 [1:5000 in 
5% (w/v) nonfat milk blocking buffer, 2 hours at room temperature; 
Ab10799, Abcam]. A high-sensitivity chemiluminescence HRP de-
tection kit was used (Amersham ECL Prime Western Blotting De-
tection Reagent, RPN2232).
Transient transfection/dual luciferase assay
Luciferase assays were performed according to the kit manufacturer 
protocol (cat# E1910, Promega). Briefly, 15,000 HEK293 cells were 
plated in a white-bottom 96-well tissue culture plate. The following 
day, 0.2 ng of Renilla control vector (pRL-CMV, cat# E2261, Promega), 
20 ng of empty or enhancer-containing promotor-pGL4 (pGL4:23, 
cat# E841A, Promega), and 20 ng of either empty or CEBPA-construct 
containing pcDNA3 (MSC-154) (Thermo Fisher Scientific) vector 
were transfected using a 3:1 l/g ratio of TransIT-2020 (MIR 5404, 
Mirus) reagent. After a 24-hour incubation, readouts were obtained 
using a standard luminometer. Constructs used include pcDNA3- 
Cebpa(WT) and pcDNA3-Cebpa(p30) expression constructs, and 
pGL4:23 containing human and mouse putative NT5E/Nt5e enhancers 
cloned to the multiple cloning site with the primers listed in data 
file S7. The human enhancer was first cloned to the TOPO vector 
(pCR-2.1-Topo, K450002, Thermo Fisher Scientific) and then cloned 
using Kpn I and Xho I restriction enzymes. The mouse enhancer 
was cloned directly from PCR with the same restriction enzymes.
mRNA–RT-qPCR expression analysis
For expression analysis, cells were sorted as described above, RNA- 
extracted using the RNeasy Micro Kit (QIAGEN) or NucleoSpin 
RNA XS (MN), and reverse-transcribed to cDNA using the ProtoScript 
First Strand cDNA Synthesis Kit (M-MuLV) and oligo (dT) primers 
(NEB). RT-qPCR was performed using LightCycler 480 SYBR Green 
I Master (Roche Life Sciences). Data were normalized to Actg1 (mouse) 
or POL2AR and H6PD (human). Primers used are listed in data file S7.
Preparation of human cDNA libraries and sequencing
Total RNA was extracted from GMPs using the RNeasy Micro Kit 
(QIAGEN). Thirty nanograms of RNA was processed for double- 
stranded cDNA synthesis with the Ovation RNA-Seq System V2 
(NuGEN Technologies). Subsequently, 1 g of the sheared cDNA 
[fragment size, 200 to 600 base pairs (bp)] was subjected to library 
preparation according to the Illumina TruSeq DNA Sample Prepara-
tion Kit (ref #15012999) protocol. The indexed libraries were pooled 
in equimolar ratios and subjected to 100-bp paired-end sequencing 
on the Illumina HiSeq 2000 system.
Preparation of Lp30 cDNA libraries and sequencing
Recipient mice were transplanted with shRNA-transduced Lp30 cells 
(1.5 × 106 for each Nt5e knockdown construct and 0.5 × 106 for scrambled 
control). Three weeks after BMT, 5 × 105 GFP-sorted cells from two 
or three individual mice per construct were used for mRNA extraction 
(RNeasy mini kit, QIAGEN), and cDNA library was generated using 
600 ng of input RNA (TruSeq Library RNA Prep Kit v2, Illumina). 
Libraries were diluted and sequenced (NextSeq, Illumina).
Mapping and quantification of RNA-seq data
See Supplementary Materials and Methods for detailed description.
Mass spectrometry
Detailed description of the procedure can be found in Supplemen-
tary Materials and Methods. Briefly, FACS-sorted cells were washed 
twice with ice-cold PBS and lysed in 6 M guanidinium hydrochloride, 
10 mM tris(2-carboxyethyl)phosphine, 40 mM 2-chloroacetamide, 
and 100 mM tris (pH 8.5). Proteins were digested first with LysC 
and subsequently with trypsin at 37°C. Enzyme activity was quenched 
by trifluoroacetic acid (TFA) at a final concentration of 1%. Before 
mass spectrometry (MS) analysis, the peptides were desalted on in-
house packed C18 StageTips. Samples were analyzed in a label-free 
manner, where each sample was loaded onto a 2-cm C18 trap column, 
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connected in line to a 50-cm C18 reverse-phase analytical column 
(Easy-Spray ES803, Thermo Fisher Scientific). Peptides were elut-
ed over a 200-min gradient, ranging from 5 to 48% of acetonitrile 
at 250 nl/min, and analyzed in a ddMS2-IT-HCD top speed method 
on an Orbitrap Fusion (Thermo Fisher Scientific). MS performance 
was verified for consistency by running complex cell lysate quality 
control standards, and chromatography was monitored to check for 
reproducibility.
Chromatin preparation and immunoprecipitation
ChIP on both mouse and human samples was performed as de-
scribed previously (49, 50), with the exception that amplification for 
the human ChIP samples was done with the New England Biolabs 
Ultra Amplification Kit (cat# E7370, NEB) and no Escherichia coli 
carrier DNA. Specific washing conditions not mentioned previously 
include four times low-salt (140 mM NaCl) radioimmunoprecipitation 
assay (RIPA) buffer washes for both H3K4me1 and H3K27ac pre-
cipitations, replacing all high-salt (500 mM) washes [see (50) for 
detailed protocol]. Abs used were CEBPA (clone 14AA, sc-61, Santa 
Cruz Biotechnology), H3K4me1 (ab8895, Abcam), and H3K27ac (ab4729, 
Abcam). See primer table (data file S7) for primer sets used for as-
sessing the quality of each individual precipitation.
Mapping and quantification of ChIP-seq data
See Supplementary Materials and Methods for detailed description.
3C-qPCR
3C was done essentially as described previously (51) with some 
modifications. Specifically, mouse Lp30 leukemic GMP cells (Lin– cKit+ 
Sca1– CD150– CD41– FcgRII/III+) were isolated by FACS, while 
cKit+ WT BM cells were isolated by magnetic-activated cell sorting 
(MACS) (CD117 magnetic microbeads, Miltenyi Biotech) for com-
parison. Approximately 2 million cells were used per reaction, fixed 
in 1.5% formaldehyde in 10 ml of cold PBS/RPMI medium 50%/50% 
rotating at room temperature for 10 min, and quenched for 2 min in 
187 mM of added glycine. Lysis was done by douncing (glass) 10 strokes 
on ice after 15 min of incubation on ice. Cell fragments/nuclei were 
recovered by centrifugation at 2200g for 5 min at 4°C and washed 
once in ice-cold restriction buffer and resuspended in 0.5 ml of re-
striction buffer. Chromatin was exposed for digestion by a 1-hour 
incubation with 0.1% of SDS at 37°C, followed by a 1-hour incubation 
with 1% Triton X-100 at 37°C. Overnight digestion with 200 U of 
Xba I (R0145T, NEB) with the addition of 100 U of enzyme for the 
last 4 hours was followed by 30 min of heat inactivation at 65°C. Liga-
tion was performed with 20,000 U of T4 ligase (M0202T, NEB) for 
3 hours at 20°C. DNA was isolated by RNase A (19101, QIAGEN) 
exposure for 30 min, followed by addition of 1 mg of proteinase K 
(P6556, Sigma-Aldrich) and incubation in 0.4% SDS for 2 hours and 
phenol- chloroform extraction using phase-lock tubes (713-2536, 
5-prime). RT-qPCR was performed as described above, with qua-
druplicates for each data point and a high-stringency, 50-cycle 
program. All primers are listed in data file S7.
Statistical analysis
The statistical analyses used, the definition of what n represents, 
and the meaning of numbers of asterisks are indicated for each experi-
ment in the relevant figure legends. For BMT experiments, recipient 
mice were randomized to receive control and test leukemic cells, 
respectively. For survival analysis, individual mice were shuffled 
between cages. See Supplementary Materials and Methods. No blinding 
of experimental groups was performed. No statistical method was 
applied to predetermine sample sizes, but sample sizes are indicated 
in relevant figures.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/7/eaaw4304/DC1
Supplementary Materials and Methods
Fig. S1. Distinct enhancer-binding of CEBPA in WT GMPs versus p30 L-GMPs, related to Fig. 1.
Fig. S2. Motif enrichment analysis of p42, common and p30 CEBPA-bound regions, related to Fig. 2.
Fig. S3. Gene expression analysis of murine and human CEBPA mutant AML, related to Fig. 3.
Fig. S4. CEBPA-p30 directly activates the expression of Nt5e, related to Fig. 4.
Fig. S5. CD73-positive GMPs in human AML and CBF-MYH binding of the NT5E promoter in 
INV(16) AML, related to Fig. 5.
Fig. S6. A2AR-dependent adenosinergic autocrine survival signaling promoted by CD73, 
related to Fig. 6.
Data File S1. CEBPA-peak coordinates, enriched motifs in CEBPA regions, related to Fig. 1.
Data File S2. RNA-seq data, related to Figs. 2 and 3.
Data File S3. MS data, related to Figs. 2 and 3.
Data File S4. Gene signatures, related to Fig. 3.
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